GlaxoSmithKline plc Rating Reiterated by Liberum Capital (GSK)
GlaxoSmithKline plc (LON:GSK) traded up 0.09% during mid-day trading on Friday, hitting GBX 1591.50. The stock had a trading volume of 12,884,379 shares. GlaxoSmithKline plc has a 1-year low of GBX 1200.668 and a 1-year high of GBX 1762.0001. The stock has a 50-day moving average of GBX 1612. and a 200-day moving average of GBX 1615.. The company’s market cap is £76.615 billion.
A number of other analysts have also recently weighed in on GSK. Analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Thursday. They now have a GBX 1,610 ($27.33) price target on the stock. Separately, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of GlaxoSmithKline plc in a research note on Wednesday. They now have a GBX 1,650 ($28.01) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Tuesday. They now have a GBX 1,700 ($28.86) price target on the stock. Four equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the company. GlaxoSmithKline plc presently has a consensus rating of “Hold” and an average price target of GBX 1,726.48 ($29.31).
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.